Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

This study has been terminated.
(Accrual was too slow. Trial terminated)
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Ephraim Hochberg, MD, Massachusetts General Hospital Identifier:
First received: April 2, 2007
Last updated: October 23, 2012
Last verified: October 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)